KR102764125B1 - 혈액암 치료를 위한 조합요법 - Google Patents

혈액암 치료를 위한 조합요법 Download PDF

Info

Publication number
KR102764125B1
KR102764125B1 KR1020217009727A KR20217009727A KR102764125B1 KR 102764125 B1 KR102764125 B1 KR 102764125B1 KR 1020217009727 A KR1020217009727 A KR 1020217009727A KR 20217009727 A KR20217009727 A KR 20217009727A KR 102764125 B1 KR102764125 B1 KR 102764125B1
Authority
KR
South Korea
Prior art keywords
pyridin
pyrazol
axl
bcl
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217009727A
Other languages
English (en)
Korean (ko)
Other versions
KR20210061356A (ko
Inventor
자이후이 장
샤오얀 지앙
캐서리나 로테
샤오지아 니우
Original Assignee
시그널켐 라이프사이언시즈 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그널켐 라이프사이언시즈 코포레이션 filed Critical 시그널켐 라이프사이언시즈 코포레이션
Publication of KR20210061356A publication Critical patent/KR20210061356A/ko
Application granted granted Critical
Publication of KR102764125B1 publication Critical patent/KR102764125B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020217009727A 2018-09-18 2019-09-18 혈액암 치료를 위한 조합요법 Active KR102764125B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862732816P 2018-09-18 2018-09-18
US62/732,816 2018-09-18
PCT/US2019/051764 WO2020061216A1 (en) 2018-09-18 2019-09-18 Combination therapy for treating blood cancer

Publications (2)

Publication Number Publication Date
KR20210061356A KR20210061356A (ko) 2021-05-27
KR102764125B1 true KR102764125B1 (ko) 2025-02-07

Family

ID=68104787

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217009727A Active KR102764125B1 (ko) 2018-09-18 2019-09-18 혈액암 치료를 위한 조합요법

Country Status (13)

Country Link
US (1) US12097194B2 (https=)
EP (1) EP3852766B1 (https=)
JP (1) JP7460639B2 (https=)
KR (1) KR102764125B1 (https=)
CN (1) CN112739349B (https=)
AU (1) AU2019343044B2 (https=)
BR (1) BR112021005054A2 (https=)
CA (1) CA3110901C (https=)
IL (1) IL281439B2 (https=)
MX (1) MX2021003062A (https=)
SG (1) SG11202101955SA (https=)
TW (1) TWI824010B (https=)
WO (1) WO2020061216A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
EP3737681A4 (en) 2018-01-10 2022-01-12 Recurium IP Holdings, LLC BENZAMIDE COMPOUNDS
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
MX2022005375A (es) 2019-11-05 2022-10-07 Abbvie Inc Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con neoplasias mieloproliferativas (nmp) con navitoclax.
IL316201A (en) 2022-04-08 2024-12-01 Eikonizo Therapeutics Inc Oxadiazole HDAC6 inhibitors and their uses
WO2025170888A1 (en) * 2024-02-05 2025-08-14 Signalchem Lifesciences Corporation A combination of the axl inhibitor slc-391 and a pd-1 inhibitor for use in the treatment of blood cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
EP1888550B1 (en) 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
SG172997A1 (en) * 2009-01-16 2011-08-29 Rigel Pharmaceuticals Inc Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
TWI620736B (zh) 2010-11-23 2018-04-11 艾伯維巴哈馬有限公司 使用選擇性ｂｃｌ-２抑制劑之治療方法
WO2014020043A1 (en) * 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
JP6496731B2 (ja) * 2013-11-27 2019-04-03 シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｔａｍファミリーキナーゼ阻害剤としてのアミノピリジン誘導体
AU2015211021B2 (en) * 2014-01-28 2020-07-02 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
CN106458914B (zh) * 2014-03-28 2020-01-14 常州捷凯医药科技有限公司 作为axl抑制剂的杂环化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Curr. Hematol. Malig. Rep., 13(4), pp.256-264(2018.08.) 1부.*

Also Published As

Publication number Publication date
SG11202101955SA (en) 2021-03-30
CA3110901C (en) 2024-01-02
TWI824010B (zh) 2023-12-01
WO2020061216A1 (en) 2020-03-26
KR20210061356A (ko) 2021-05-27
JP7460639B2 (ja) 2024-04-02
CN112739349B (zh) 2024-03-01
AU2019343044B2 (en) 2025-03-06
CN112739349A (zh) 2021-04-30
EP3852766B1 (en) 2024-05-08
US20220031685A1 (en) 2022-02-03
JP2022501434A (ja) 2022-01-06
IL281439B2 (en) 2025-02-01
US12097194B2 (en) 2024-09-24
MX2021003062A (es) 2021-05-27
BR112021005054A2 (pt) 2021-06-08
IL281439A (en) 2021-04-29
AU2019343044A1 (en) 2021-03-18
IL281439B1 (en) 2024-10-01
CA3110901A1 (en) 2020-03-26
TW202023554A (zh) 2020-07-01
EP3852766A1 (en) 2021-07-28

Similar Documents

Publication Publication Date Title
KR102764125B1 (ko) 혈액암 치료를 위한 조합요법
JP7476380B2 (ja) 血液学的障害を治療するための化合物および組成物
AU2019315487B2 (en) Combination product of Bcl-2 inhibitor or Bcl-2/Bcl-xl dual inhibitor and BTK inhibitor and use thereof in the prevention and/or treatment of diseases
EP4115887A1 (en) Pharmaceutical composition for prevention or treatment of cancer in which kras mutation and activated ron are present
JP2023520333A (ja) Ｅｉｆ４ａ阻害剤組み合わせ
JP6180420B2 (ja) 増殖性疾患の治療のためのｈｓｐ９０阻害剤と組み合わせた２−カルボキサミドシクロアミノウレア誘導体
BR112019019101A2 (pt) compostos macrocíclicos como inibidores de ros1 cinase
AU2017220738A1 (en) Carboxamide derivatives useful as RSK inhibitors
JP2020512343A (ja) 血液疾患を処置するための化合物及び組成物
BR112021002632A2 (pt) compostos e composições de ureia como inibidores de smarca2/brm atpase
BR112014021519B1 (pt) Compostos de piperidina ou sais dos mesmos e inibidor seletivo de aurora a, composição farmacêutica, agente antitumoral e agente de potencialização de efeito antitumoral de um agonista de microtúbulos compreendendo os ditos compostos, bem como usos terapêuticos dos ditos composto
EP3479843A1 (en) Use of nox inhibitors for treatment of cancer
CA2608171C (en) Use of quinolinone compounds for treating drug resistant cancers
KR20220101656A (ko) 병용 의약
US9549921B2 (en) Heterocyclic compounds and methods of use thereof for the treatment of hepatitis C
CN112237579A (zh) 药物组合及其用途
HK40042345A (en) Combination therapy for treating blood cancer
HK40042345B (zh) 用於治疗血癌的组合疗法
JP2026507880A (ja) がんを治療する方法
US20250235453A1 (en) Triazolopyridazine compounds useful as rac1 inhibitors
HK40035225A (en) Pharmaceutical combination and use thereof
HK1110477B (en) Methods for treating drug resistant cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210401

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220705

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20241028

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250108

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250203

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250204

End annual number: 3

Start annual number: 1

PG1601 Publication of registration